Mumbai-based pharma major Lupin Limited has received approval from the European Commission for its biosimilar ranibizumab, branded as Ranluspec (available in vials and pre-filled syringes). The approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP).
This marks an important milestone for Lupin as it expands its presence in the biologics segment in Europe.
Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), which is responsible for abnormal blood vessel growth in the eye.
The medicine is used to treat several serious eye conditions, including:
These conditions can lead to vision loss if not treated properly.
Thierry Volle, President – EMEA and Emerging Markets at Lupin, said the approval highlights the company’s strong scientific capabilities and manufacturing quality. He added that Lupin remains committed to making innovative and affordable biologic treatments available to more patients worldwide.
Dr. Cyrus Karkaria, President – Biotechnology at Lupin, described the approval as a major milestone that reflects the company’s high scientific standards and focus on improving access to advanced therapies.
Read More: India’s Forex Reserves Rise by $8.66 Billion to Reach Record $725.7 Billion.
Lupin’s biosimilar ranibizumab will be marketed across the European Union (excluding Germany) by Sandoz. In France, the product will be commercialized by both Sandoz and Biogaran.
Founded and headquartered in Mumbai, Lupin is a global pharmaceutical company with a presence in more than 100 markets. The company focuses on branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients.
Lupin share price (NSE: LUPIN) closed at ₹2,247.00 on February 23, 2026, rising ₹27.60 or 1.24% for the day. The stock opened at ₹2,220.00 and touched an intraday high of ₹2,254.40 and a low of ₹2,210.50. During the session around 2:50 PM IST, it was trading at ₹2,233.80. The stock’s 52-week high stands at ₹2,263.00, while its 52-week low is ₹1,795.20. Lupin offers a dividend yield of 0.53%, with a quarterly dividend amount of ₹2.98.
The European Commission’s approval of Lupin’s biosimilar Ranluspec strengthens the company’s position in the biologics space and expands its footprint in Europe. With partnerships in place for commercialisation, Lupin is set to improve access to affordable treatments for serious eye diseases across the region.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
Published on: Feb 23, 2026, 3:58 PM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
